

Remplir™ Nerve Repair used in 23 Surgeries on Injured Soldiers in Ukraine

- Remplir has been used in 23 surgical procedures in Ukraine on soldiers who have sustained nerve injuries during combat
- Remplir is designed to connect, protect and cap severed nerves resulting from trauma
- Surgeons in the region, trained remotely by Orthocell's Key Opinion Leader Dr Alex O'Beirne, have provided positive feedback regarding its use in nerve repair procedures
- The Company is evaluating further opportunities to support ongoing and future engagement with defence organisations globally
- Remplir has a three-year shelf life, can be stored at room temperature, and is lightweight and easily transportable, supporting its use in these environments

Perth, Australia; 18 March 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce that its Remplir™ nerve repair device has recently been used in 23 surgical procedures on injured soldiers in Ukraine.

Following a humanitarian delivery of Remplir to Ukraine in April 2025, Orthocell has now received confirmation that the device has been successfully utilised by Ukrainian surgeons in both primary and secondary nerve repair procedures. Surgeon feedback has been very positive, supporting the clinical utility of the device.

This real-world use in a conflict setting highlights key attributes of Remplir, including its portability, ease of use, and suitability for major trauma applications in the defence forces.

Importantly, Orthocell provided remote training to Ukrainian surgeons via video, supported by Australian Orthopedic Surgeon and Orthocell Key Opinion Leader Dr Alex O'Beirne, who delivered a comprehensive training module. The successful adoption of Remplir following remote instruction further demonstrates the practicality and accessibility of the device in challenging environments.

Orthocell intends to continue engagement with Ukrainian surgeons to monitor patient outcomes and, where possible, collect clinical data. This information is expected to support ongoing and future discussions with defence organisations globally.

Orthocell Managing Director Paul Anderson said: "In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution."

The Company also acknowledges the support of Vasyl Myroshnychenko, Ambassador of Ukraine to Australia, who has played an important role in facilitating engagement and coordination with Ukrainian stakeholders.

Release authorised by:

Paul Anderson

Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres

H^CK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy

VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important

factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.